At1-receptor antagonists for treating nephrotic syndrome

Details At1-receptor antagonists for treating nephrotic syndrome At1-receptor antagonists for treating nephrotic syndrome

A - Human Necessities

61

K

A61K 31/41 (2006.01) A61K 31/366 (2006.01) A61K 31/40 (2006.01) A61K 31/404 (2006.01) A61K 31/4178 (2006.01) A61K 31/4184 (2006.01) A61K 31/4188 (2006.01) A61K 31/4196 (2006.01) A61K 31/4439 (2006.01) A61K 31/47 (2006.01) A61K 31/4709 (2006.01) A61K 31/505 (2006.01) A61P 13/12 (2006.01)

Patent

CA 2544747

The compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'(lH-tetrazol- 5-~yl)biphenyl-4-yl-methyl]amine (valsartan) of formula (I) or a salt thereof, in particular a pharmaceutically acceptable salt thereof, can be used for treating nephrotic syndrome.

L'invention concerne un composé (S)-N-(1-carboxy-2-méthylprop-1-yl)-N-pentanoyl-N-[2'(lH-tétrazol-5--yl)biphényl-4-yl-méthyl]amine (valsartan) de formula (I) ou un sel de celui-ci, notamment, un sel acceptable sur le plan pharmaceutique de celui, pouvant être utilisé pour traiter le syndrome néphrotique.

Affiliated with

Also associated with

Rating

At1-receptor antagonists for treating nephrotic syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with At1-receptor antagonists for treating nephrotic syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and At1-receptor antagonists for treating nephrotic syndrome will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1601175